tiprankstipranks
Novartis initiated with an Underweight at Morgan Stanley
PremiumThe FlyNovartis initiated with an Underweight at Morgan Stanley
20d ago
Novartis agrees to acquire Anthos for up to $3.1B
Premium
The Fly
Novartis agrees to acquire Anthos for up to $3.1B
21d ago
Hold Rating for Novartis AG Due to Limited Potential of Abelacimab Despite Acquisition of Anthos Therapeutics
Premium
Ratings
Hold Rating for Novartis AG Due to Limited Potential of Abelacimab Despite Acquisition of Anthos Therapeutics
21d ago
Novartis price target raised to CHF 90 from CHF 85 at Barclays
PremiumThe FlyNovartis price target raised to CHF 90 from CHF 85 at Barclays
28d ago
Novartis AG Earnings Call Highlights Strong Growth and Strategic Challenges
Premium
Company Announcements
Novartis AG Earnings Call Highlights Strong Growth and Strategic Challenges
1M ago
Navigating Risks: Novartis’s Strategic Challenges in Expanding Innovative Medicines Portfolio
Premium
Company Announcements
Navigating Risks: Novartis’s Strategic Challenges in Expanding Innovative Medicines Portfolio
1M ago
Novartis Reports Strong 2024 Financial Performance and Innovation Milestones
PremiumCompany AnnouncementsNovartis Reports Strong 2024 Financial Performance and Innovation Milestones
1M ago
Novartis reports Q4 core EPS $1.98 vs. $1.53 last year
Premium
The Fly
Novartis reports Q4 core EPS $1.98 vs. $1.53 last year
1M ago
Novartis proposes 6.1% dividend increase to CHF 3.50 per share for 2024
Premium
The Fly
Novartis proposes 6.1% dividend increase to CHF 3.50 per share for 2024
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100